Biofarm Bucure Market Cap ($309.97 Million)
Market Cap & Net Worth: Biofarm Bucure (BIO)
Biofarm Bucure market cap. Biofarm Bucure (RO:BIO) has a market capitalization of $309.97 Million (RON1.35 Billion) as of November 1, 2026. Listed on the RO stock exchange, this Romania-based company holds position #14351 globally and #20 in its home market, demonstrating a 3.01% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biofarm Bucure's stock price RON1.37 by its total outstanding shares 985367224 (985.37 Million). Also see how efficiently does Biofarm Bucure generate cash for how efficiently the company converts equity into cash flow.
Biofarm Bucure Market Cap History (2015–2026)
Biofarm Bucure market cap history from 2015 to 2026. Data shows growth from $41.11 Million to $309.97 Million (19.77% CAGR). Check Biofarm Bucure stock quote for real-time trading data and today's change.
Index Memberships
Biofarm Bucure is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Bucharest Plus Index
BETPLUS
|
$69.11 Billion | 0.45% | #13 of 42 |
Weight: Biofarm Bucure's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Biofarm Bucure Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biofarm Bucure's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Biofarm Bucure to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.57x
Biofarm Bucure's market cap is 0.57 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1.82x
Biofarm Bucure's market cap is 1.82 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $64.98 Million | $195.32 Million | $50.88 Million | 0.33x | 1.28x |
| 2020 | $82.76 Million | $216.42 Million | $54.26 Million | 0.38x | 1.53x |
| 2021 | $167.27 Million | $239.04 Million | $60.36 Million | 0.70x | 2.77x |
| 2022 | $128.31 Million | $276.98 Million | $70.92 Million | 0.46x | 1.81x |
| 2023 | $179.26 Million | $280.29 Million | $77.01 Million | 0.64x | 2.33x |
| 2024 | $161.55 Million | $286.77 Million | $74.40 Million | 0.56x | 2.17x |
| 2025 | $183.27 Million | $319.33 Million | $100.82 Million | 0.57x | 1.82x |
Competitor Companies of BIO by Market Capitalization
Companies near Biofarm Bucure in the global market cap rankings as of November 1, 2026. Also see BIO asset base for a full breakdown of the balance sheet.
Key companies related to Biofarm Bucure by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.62 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of Biofarm Bucure (2015–2026)
Market capitalization of Biofarm Bucure from 2015 to today. Between 2015 and today, Biofarm Bucure's market cap moved from $41.11 Million to $ 309.97 Million, with a yearly change of 19.77%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | RON309.97 Million | +69.14% |
| 2025 | RON183.27 Million | +13.45% |
| 2024 | RON161.55 Million | -9.88% |
| 2023 | RON179.26 Million | +39.71% |
| 2022 | RON128.31 Million | -23.29% |
| 2021 | RON167.27 Million | +102.10% |
| 2020 | RON82.76 Million | +27.37% |
| 2019 | RON64.98 Million | +15.16% |
| 2018 | RON56.43 Million | +17.92% |
| 2017 | RON47.85 Million | +14.02% |
| 2016 | RON41.97 Million | +2.09% |
| 2015 | RON41.11 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Biofarm Bucure was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $309.97 Million USD |
| MoneyControl | $309.97 Million USD |
| MarketWatch | $309.97 Million USD |
| marketcap.company | $309.97 Million USD |
| Reuters | $309.97 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Biofarm Bucure
Biofarm S.A. manufactures and sells medicines in Romania. The company offers a portfolio of products covering therapeutic areas, such as antiallergics, cardiovascular and circulatory, analgesics and antipyretics, dermatology, digestive and metabolic, endocrine, genitourinary, multivitamins, ophthalmology, musculoskeletal, respiratory and ENT, and neurology. It provides prescription and non-prescr… Read more